Table 4c.

Recent Studies of Pharmacologic Anticoagulants in Ambulatory Cancer Patients

Citation	Patient Population	Treatments	Primary Outcome	Result	Significance Level	Bleeding Rates	Significance Level	Length of Treatment	Setting
Cini M, et al. Eur J Haematol. 201085	Multiple myeloma	Thalidomide- dexamethasone or thalidomide- dexamethasone + warfarin	VTE	No prophylaxis 26.3% (5/19); warfarin 10.6% (26/246)	P=.095	Major bleeding: none recorded	Not specified	120 d	Prophylaxis
Agnelli G, et al. Lancet Oncol. 200943	Lung, GI, pancreatic, breast, ovarian, or head and neck cancer	Nadroparin 3800 IU QD or placebo	Composite of symptomatic venous or arterial thromboembolic events	Nadroparin 2.0% (5/769); placebo 3.9% (5/381)	P=.02	Major bleeding: nadroparin 0.7%; placebo 0%	P=.18	≤4 mo	Prophylaxis
Lee AY, et al. J Clin Oncol. 200586	Patients with solid tumors and VTE	Dalteparin 200 U/kg QD X 1 mo then 150 U/kg QD X 5 mo or dalteparin 200 U/kg X 7 d then INR-adjusted coumarin derivative X 6 mo	All-cause mortality at 12 mo	Dalteparin 20% (15/75); warfarin 36% (26/75) in patients with no metastases	P=.03	Not specified	Not specified	6 mo	Prophylaxis
Hull RD, et al. Am J Med. 200687	Patients with cancer and VTE	Tinzaparin 175 U/kg QD vs usual care (UFH + warfarin)	Recurrent VTE or death at 3 mo	Recurrent VTE: tinzaparin 6% (6/100); usual care 10% (10/100) death: tinzaparin 20% (20/100); usual care 19% (19/100)	Recurrent VTE P=NS; death P=NS	Major bleeding: tinzaparin 7%; usual care 7%	P=NS	3 mo	Treatment
Romera A, et al. Eur J Vasc Endovasc Surg. 200988	Patients with VTE including 28.6% (69/241) with cancer	Tinzaparin 175 IU/kg QD or INR-adjusted acenocoumarol	Recurrent VTE at 6 mo and 1 yr	Cancer population: 6 mo: tinzaparin 5.5% (2/36); warfarin 9.1% (3/33). 1 yr: tinzaparin 5.5% (2/36); warfarin 21.2% (7/33)	6 mo P=.58; 1 yr P=.06	Major bleeding in total population: tinzaparin 0.8%; warfarin 2.5%	P=.6	6 mo	Treatment